Siri Lillegraven
Utdanning
- Cand.med., Universitet i Oslo (profesjonsstudiet i medisin)
- Master of Public Health, Harvard School of Public Health
- Doktorgrad ved Institutt for klinisk medisin, Universitetet i Oslo
Stilling
- Nestleder, Forskningssenter for behandling innen revmatologi og muskelskjelettsykdommer (REMEDY), Diakonhjemmet sykehus
- Leder for Enhet for klinisk forskning, Diakonhjemmet sykehus
- Førsteamanuensis, Institutt for helse og samfunn, Universitetet i Oslo
Interessefelt
- Kliniske studier innen ortopedi og revmatologi med spesielt fokus på randomisert-kontrollerte studier
Annet
- Leder av arbeidspakke 1 i REMEDY (Behandlingsstudier)
- Mottaker av Marie Spångberg-prisen 2022
E-post
Telefon
Besøksadresse
Diakonhjemmet sykehus
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo
Postadresse
Diakohjemmet sykehus
Postboks 23 Vinderen
0319 Oslo
Prosjekter
ARCTIC
Remisjon hos pasienter med revmatoid artritt: en randomisert kontrollert studie som undersøker bruk av ultralyd i klinisk oppfølging
Prosjektleder:
Espen A. HaavardsholmARCTIC FORWARD
10-års oppfølging av pasienter med revmatoid artritt som mottok strukturert behandling-til-mål-terapi i tidlig sykdomsfase.
Prosjektleder:
Siri LillegravenARCTIC REWIND
10-års oppfølging av pasienter med revmatoid artritt som mottok strukturert behandling-til-mål-terapi i tidlig sykdomsfase.
Prosjektleder:
Espen A. HaavardsholmProsjektleder:
Siri LillegravenProsjektleder:
Siri LillegravenProsjektleder:
Hilde Berner HammerNOR-Flare
Avstandsoppfølging av pasienter med revmatoid artritt
Prosjektleder:
Anne Therese TveterNOR-Sprint
Oppfølging av nydiagnostiserte pasienter med psoriasisartritt med og uten bildediagnostikk
Prosjektleder:
Siri LillegravenOA-AID
Digitale mestringsverktøy og digital oppfølging for å støtte samvalg i behandling av pasienter med kneartrose
Prosjektleder:
Anne Therese TveterSQUEEZE
Maksimering av effekten av reseptbelagte legemidler ved revmatoid artritt
Prosjektleder:
Espen A. HaavardsholmPublikasjoner
Publikasjoner hentet fra Nasjonalt vitenarkiv (NVA):
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial
The Lancet Rheumatology
Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials
RMD Open
Follow-Up of Patients With Axial Spondyloarthritis in Specialist Health Care With Remote Monitoring and Self-Monitoring Compared With Regular Face-to-Face Follow-Up Visits (the ReMonit Study): Protocol for a Randomized, Controlled Open-Label Noninferiority Trial
JMIR Research Protocols
Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
Annals of the Rheumatic Diseases
Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis and Excellent Disease Control
Journal of the American Medical Association (JAMA)
Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
Annals of the Rheumatic Diseases
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial
Journal of the American Medical Association (JAMA)
Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-To-Target strategy
RMD Open
Rheumatoid Arthritis Patients, Both Newly Diagnosed and Methotrexate Treated, Show More DNA Methylation Differences in CD4+ Memory Than in CD4+ Naïve T Cells
Frontiers in Immunology
Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
RMD Open
The impact of ultrasound on the use and efficacy of intraarticular glucocorticoid injections in early rheumatoid arthritis: Secondary analyses from a randomized trial examining the benefit of ultrasound in a clinical tight control regimen
Arthritis & Rheumatology
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy
Arthritis Research & Therapy
Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: Associations to future good radiographic and physical outcomes
Annals of the Rheumatic Diseases
Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria
Annals of the Rheumatic Diseases
The OMERACT-RAMRIS Rheumatoid Arthritis Magnetic Resonance Imaging Joint Space Narrowing Score: Intrareader and Interreader Reliability and Agreement with Computed Tomography and Conventional Radiography
Journal of Rheumatology
Development and Preliminary Validation of a Magnetic Resonance Imaging Joint Space Narrowing Score for Use in Rheumatoid Arthritis: Potential Adjunct to the OMERACT RA MRI Scoring System
Journal of Rheumatology